Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (NCT04114825)
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)
🩺 Plain-English Summary (8th-Grade Level)
This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).
Who can join: Review the eligibility criteria below.
Location: Tampa Bay Medical Research — Clearwater, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Tampa Bay Medical Research — Clearwater, Florida
- Chesapeake Urology Research Associates — Towson, Maryland
- GU Research Network/Urology Cancer Center — Omaha, Nebraska
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Icahn School of Medicine at Mount Sinai Hospitals — New York, New York
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- The Urology Place — San Antonio, Texas
- Gent University Hospital — Ghent,
- CHU de Liège — Liège,
- Hôpital Erasme — Liège,
- Aalborg University, Departmen of Urology — Aalborg,
- Aarhus University Hospital, Department of Urology — Aarhus,
- Rigshospitalet, Copenhagen Prostate Cancer Center — Copenhagen,
- Herlev & Gentofte Hospital, Department of Urology — Herlev,
- Urinvejskirurgisk afdeling, Hospitalsenheden Vest — Holstebro,
- Odense University Hospital, Deparment of Urology — Odense,
- Meilahti Tower Hospital — Helsinki,
- Oulu University Hospital — Oulu,
- Seinajoki Central Hospital — Seinäjoki,
- Tampere University Hospital — Tampere,
- Turku University Hospital — Turku,
- University Hospital Dresden — Dresden,
- Urologicum Duisburg — Duisburg,
- Urologische Praxis Dr. Wolfgang Warnack — Hagenow,
- Urologische Praxis. M. Markov — Halle,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer Recurrent
- Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer — Toronto, Ontario
- Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer — Indianapolis, Indiana
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer — Charleston, South Carolina
- Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era — Toronto, Ontario
Explore by condition: All Prostate Cancer Recurrent clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.